Roles of Sodium-Glucose Cotransporter 1 (SGLT1) in the Induction of Cardiac Remodeling
- 1 July 2018
- journal article
- review article
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 138 (7), 939-943
- https://doi.org/10.1248/yakushi.17-00223-2
Abstract
It is well-known that metabolic remodeling occurs in the presence of cardiomyopathy induced by cardiac ischemia and hypertrophy, and diabetes mellitus. It is also known that a novel cardiac glucose transporter, sodium-glucose co-transporter 1 (SGLT1), is expressed in the human heart. However, the role of SGLT1 in the development of cardiac metabolic remodeling is still unclear. Recent studies demonstrated that SGLT1 activation improves ischemia-reperfusion-induced cardiac injury, and increased SGLT1 gene expression is observed in hypertrophic, ischemic, and diabetic cardiomyopathy in human hearts. Moreover, increases in SGLT1 protein expression cause cardiac remodeling such as hypertrophy and increased interstitial fibrosis in mice. We demonstrated that ischemia-reperfusion-induced cardiac injury was potentiated in SGLT1-deficient mice. In contrast, chronic pressure overload induced by transverse aortic constriction (TAC) caused cardiac hypertrophy and reduced left ventricular fractional shortening in C57BL/6J wild-type mice. Moreover, the TAC-induced hypertrophied heart showed increased SGLT1 and AMPKαprotein expressions. These results suggest the different effects of SGLT1 activation on cardiac diseases such as acute ischemia-reperfusion-induced cardiac injury and chronically-induced cardiac hypertrophy. Thus, SGLT1 may be a novel therapeutic target for the treatment of patients with cardiac diseases such as ischemic and hypertrophic cardiomyopathy.Keywords
This publication has 10 references indexed in Scilit:
- Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological targetInternational Journal of Cardiology, 2017
- Protein kinase C–mediated sodium glucose transporter 1 activation in precondition-induced cardioprotectionDrug Design, Development and Therapy, 2016
- Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injuryBiochemical and Biophysical Research Communications, 2016
- Intracellular Na + Concentration ([Na + ] i ) Is Elevated in Diabetic Hearts Due to Enhanced Na + –Glucose CotransportJournal of the American Heart Association, 2015
- Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in MicePLOS ONE, 2015
- Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in MiceJournal of the American Heart Association, 2014
- Phlorizin Prevents Electrically-Induced Ventricular Tachyarrhythmia during Ischemia in Langendorff-Perfused Guinea-Pig HeartsBiological & Pharmaceutical Bulletin, 2014
- AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathwayArchives of Biochemistry and Biophysics, 2011
- SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathyJournal of Molecular and Cellular Cardiology, 2010
- Metabolic Remodeling Induced by Mitochondrial Aldehyde Stress Stimulates Tolerance to Oxidative Stress in the HeartCirculation Research, 2009